- Home
- BRKR vs ABVX Comparison
BRKR vs ABVX Comparison
Compare BRKR & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRKR
- ABVX
- Stock Information
- Founded
- BRKR 1960
- ABVX 2013
- Country
- BRKR United States
- ABVX France
- Employees
- BRKR N/A
- ABVX N/A
- Industry
- BRKR Biotechnology: Laboratory Analytical Instruments
- ABVX
- Sector
- BRKR Industrials
- ABVX
- Exchange
- BRKR Nasdaq
- ABVX Nasdaq
- Market Cap
- BRKR 5.3B
- ABVX 5.3B
- IPO Year
- BRKR 2000
- ABVX N/A
- Fundamental
- Price
- BRKR $32.11
- ABVX $81.00
- Analyst Decision
- BRKR Buy
- ABVX Strong Buy
- Analyst Count
- BRKR 11
- ABVX 8
- Target Price
- BRKR $50.00
- ABVX $90.63
- AVG Volume (30 Days)
- BRKR 4.6M
- ABVX 1.2M
- Earning Date
- BRKR 11-04-2025
- ABVX 08-11-2025
- Dividend Yield
- BRKR 0.62%
- ABVX N/A
- EPS Growth
- BRKR N/A
- ABVX N/A
- EPS
- BRKR 0.52
- ABVX N/A
- Revenue
- BRKR $3,442,800,000.00
- ABVX $7,073,400.00
- Revenue This Year
- BRKR $4.44
- ABVX $25.23
- Revenue Next Year
- BRKR $1.71
- ABVX N/A
- P/E Ratio
- BRKR $62.02
- ABVX N/A
- Revenue Growth
- BRKR 10.36
- ABVX N/A
- 52 Week Low
- BRKR $28.53
- ABVX $4.77
- 52 Week High
- BRKR $72.94
- ABVX $92.91
- Technical
- Relative Strength Index (RSI)
- BRKR 46.69
- ABVX 57.75
- Support Level
- BRKR $30.31
- ABVX $82.72
- Resistance Level
- BRKR $32.56
- ABVX $86.72
- Average True Range (ATR)
- BRKR 1.45
- ABVX 3.92
- MACD
- BRKR 0.30
- ABVX -1.82
- Stochastic Oscillator
- BRKR 60.58
- ABVX 20.12
About BRKR Bruker Corporation
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.